12:00 AM
Nov 16, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Optimark gadoversetamide regulatory update

Covidien said it plans to change the label for Optimark gadoversetamide injection to contraindicate its use in patients with severe renal impairment. Optimark is a gadolinium-based contrast...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >